Liver Disease Clinical Trials

A listing of Liver Disease medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Alabama

UPDATED

Research Center
Additional Locations Alabama

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

Arizona

UPDATED

Research Center
Additional Locations Arizona

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

California

UPDATED

Research Center
Additional Locations California

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

UPDATED

Contact Research Site Directly
Coronado California 92118

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

UPDATED

Contact Research Site Directly
Fresno California 93720

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

UPDATED

Contact Research Site Directly
Fresno California 93720

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

UPDATED

Contact Research Site Directly
Pasadena California 91105

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

UPDATED

Contact Research Site Directly
Pasadena California 91105

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Coronado California 92118

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Fresno California 93720

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Los Angeles California 90048

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Pasadena California 91105

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Rialto California

A clinical trial to evaluate treatments using BLU-554 for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma

Rialto California 92377

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Colorado

UPDATED

Research Center
Additional Locations Colorado

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

UPDATED

Contact Research Site Directly
Englewood Colorado 80113

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

UPDATED

Contact Research Site Directly
Englewood Colorado 80113

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Englewood Colorado 80113

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Connecticut

UPDATED

Research Center
Additional Locations Connecticut

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

Florida

UPDATED

Research Center
Additional Locations Florida

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

Gastro Florida
Clearwater Florida 33762

TARGET-NASH: A 5-year longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis

Gastro Florida
Clearwater Florida 33762

TARGET-PBC: A 5-year longitudinal observational study of patients with primary biliary cholangitis

UPDATED

Contact Research Site Directly
Wellington Florida 33414

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

UPDATED

Contact Research Site Directly
Wellington Florida 33414

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Miami Florida

A clinical trial to evaluate treatments using BLU-554 for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma

Miami Florida 33136

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Tampa Florida

A clinical trial to evaluate treatments using BLU-554 for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma

Wellington Florida 33414

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Georgia

UPDATED

Research Center
Additional Locations Georgia

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

View More ▼

Atlanta Georgia 30322

A clinical trial to evaluate treatments using Magnetic Resonance Imaging (MRI) for patients with Non-alcoholic Fatty Liver Disease

Atlanta Georgia 30312

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Marietta Georgia 30060

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Illinois

UPDATED

Research Center
Additional Locations Illinois

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

Iowa

Iowa City Iowa 52242

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Kentucky

UPDATED

Research Center
Additional Locations Kentucky

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

UPDATED

Contact Research Site Directly
Louisville Kentucky 40202

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

UPDATED

Contact Research Site Directly
Louisville Kentucky 40202

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Louisville Kentucky 40202

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Louisiana

Shreveport Louisiana 71105

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Maryland

UPDATED

Research Center
Additional Locations Maryland

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

UPDATED

Contact Research Site Directly
Baltimore Maryland 21202

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Baltimore Maryland 21202

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Catonsville Maryland 21228

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Massachusetts

Boston Massachusetts

A clinical trial to evaluate treatments using BLU-554 for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma

Worcester Massachusetts 01605

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Michigan

UPDATED

Contact Research Site Directly
Detroit Michigan 48202

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

View More ▼

Novi Michigan 48377

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Mississippi

UPDATED

Research Center
Additional Locations Mississippi

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.

View More ▼

Jackson Mississippi 39216

Patients are needed to participate in a clinical research study evaluating SHP626 and Placebo for the treatment of Non-Alcoholic Steatohepatitis

Missouri

UPDATED

Research Center
Additional Locations Missouri

Genfit is conducting the RESOLVE-IT Study, a Phase III clinical research study evaluating the investigational medication elafibranor vs. placebo for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis (scar tissue). The RESOLVE-IT Study is currently looking for qualified participants.

NASH is a progressive liver disease characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells.

RESEARCH STUDY TITLE

The RESOLVE-IT Research Study Is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.